A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST)

阿替洛尔 曲多普利 医学 内科学 血压 维拉帕米 氨氯地平 氢氯噻嗪 原发性高血压 冠状动脉疾病 血管紧张素转换酶抑制剂 血管紧张素转换酶 钙
作者
L. Douglas Ried,Michael J. Tueth,Eileen Handberg,Stuart Kupfer,Carl J. Pepine
出处
期刊:Psychosomatic Medicine [Lippincott Williams & Wilkins]
卷期号:67 (3): 398-406 被引量:61
标识
DOI:10.1097/01.psy.0000160468.69451.7f
摘要

Background: The International Verapamil/Trandolapril Study (INVEST) demonstrated comparable efficacy between verapamil SR and atenolol antihypertensive treatment strategies for clinical outcomes and blood pressure (BP) control in hypertensive patients with coronary artery disease (N = 22,576). Effects of these antihypertension strategies on mood-related issues are not well understood. Objectives: The objectives of this study were 1) to compare depressive symptoms by strategy and 2) to identify predictors of depressive symptoms in INVEST patients after 1 year of follow up. Design, Setting, and Patients: Depressive symptoms were assessed in a subset (N = 2317) of consecutively randomized U.S. patients enrolled between April 1, 1999, and October 31, 1999. Patients were mailed surveys after randomization and after 1 year of treatment. Intervention: Patients were assigned to either a verapamil SR or atenolol strategy to achieve Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure BP goals. Trandolapril and/or hydrochlorothiazide were recommended as add-on agents. Main Outcome Measure: Depressive symptoms were measured by the Center for Epidemiologic Studies–Depression (CES-D) scale. Results: CES-D scores improved 1.45 points (p < .001) after 1 year in patients assigned to the verapamil SR strategy, whereas a nonsignificant improvement was observed in patients assigned to the atenolol strategy (0.27 points, p = .44). Predictors of higher depressive symptoms were higher baseline CES-D score (p < .001), history of depression diagnosis (p = .03), history of stroke (p < .001), and assignment to the atenolol strategy (p < .001). Conclusions: A verapamil SR strategy is a viable alternative to beta-blocker therapy for hypertensive patients with coronary artery disease, especially those at risk of depression. CAD = coronary artery disease; MI = myocardial infarction; SADD-Sx = Study of Antihypertensive Drugs and Depressive Symptoms; INVEST = International Verapamil SR-Trandolapril Study; CES-D = Center for Epidemiologic Studies–Depression scale; JNC VI = Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
橘子皮发布了新的文献求助10
1秒前
兵哥完成签到,获得积分10
1秒前
rainbow完成签到,获得积分10
1秒前
毕业即胜利完成签到,获得积分10
1秒前
追寻的晓亦完成签到,获得积分20
1秒前
1秒前
壮观白风完成签到 ,获得积分10
1秒前
dcx发布了新的文献求助10
2秒前
烟花的应助被韩hh采纳,获得10
2秒前
3秒前
3秒前
饱满问夏发布了新的文献求助10
3秒前
3秒前
springlrt的应助被DRJ采纳,获得20
4秒前
aa的应助被小江采纳,获得10
4秒前
4秒前
开放凝珍发布了新的文献求助50
4秒前
pa发布了新的文献求助10
5秒前
等待的乐儿完成签到,获得积分10
5秒前
leo完成签到,获得积分10
5秒前
5秒前
Simon完成签到,获得积分10
6秒前
小蘑菇的应助被追寻的晓亦采纳,获得10
6秒前
CipherSage的应助被hh采纳,获得10
6秒前
兮九完成签到,获得积分10
6秒前
6秒前
今后的应助被心如止水采纳,获得10
6秒前
爱笑的鱼完成签到,获得积分10
7秒前
一木完成签到,获得积分10
7秒前
7秒前
shaw完成签到,获得积分10
7秒前
LengEye发布了新的文献求助10
7秒前
qiyukang完成签到,获得积分10
8秒前
8秒前
9秒前
9秒前
阳光的愚志完成签到,获得积分10
9秒前
岑岑发布了新的文献求助10
9秒前
爆米花的应助被乌鱼子采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155073
求助须知:如何正确求助?哪些是违规求助? 9551529
关于积分的说明 21705228
捐赠科研通 7744266
什么是DOI,文献DOI怎么找? 3425957
关于科研通互助平台的介绍 2551109
邀请新用户注册赠送积分活动 2469734